Exact Sciences (EXAS) director fully exits stake as Abbott closes $105-per-share merger

Rhea-AI Filing Summary

Exact Sciences Corp director James Edward Doyle reported disposing of his remaining common shares in connection with the company’s merger with Abbott Laboratories. On March 23, 2026, 52,564 shares of Exact Sciences common stock were returned to the issuer, leaving 5,398 shares. A second disposition of 5,398 shares reduced his direct holdings to zero. Under the merger agreement, each Exact Sciences share outstanding at the effective time was converted into the right to receive $105.00 in cash, and restricted shares became fully vested and cancelled for the same cash consideration, less applicable tax withholding.

Insights

M&A and insider-transactions analyst

Director’s stake is cashed out as Exact Sciences is acquired by Abbott.

The transactions show director James Edward Doyle disposing of all his Exact Sciences common stock through issuer dispositions tied to the closing of a cash merger with Abbott Laboratories. This is not an open-market sale but part of the merger mechanics.

The Form 4 reflects 52,564 shares returned first, followed by 5,398 shares, bringing his direct holdings to zero. Under the merger agreement, each share was converted into the right to receive $105.00 in cash, with restricted shares vesting and receiving the same cash consideration, less tax withholding.

These entries primarily confirm that the merger closed and equity was converted to cash at the agreed price. Any impact for investors comes from the merger terms themselves rather than from discretionary trading by the director.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Doyle James Edward

Role Director

Type	Security	Shares	Price	Value
Disposition	Common Stock	52,564	$0.00	--
Disposition	Common Stock	5,398	$0.00	--

Holdings After Transaction: Common Stock — 5,398 shares (Direct)

Footnotes (1)

1. On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doyle James Edward

(Last) (First) (Middle)

EXACT SCIENCES CORP.

5505 ENDEAVOR LANE

(Street)

MADISON WISCONSIN 53719

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXACT SCIENCES CORP [ EXAS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/23/2026		D		52,564	D	(1)	5,398	D
Common Stock	03/23/2026		D		5,398	D	(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").

2. At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

	/s/ James Edward Doyle by Mark Busch, attorney-in- fact	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did James Edward Doyle report for Exact Sciences (EXAS)?

James Edward Doyle reported two issuer dispositions of Exact Sciences common stock. He returned 52,564 shares, then 5,398 shares, reducing his direct holdings to zero as part of the closing of a cash merger with Abbott Laboratories at $105.00 per share.

How is the Abbott Laboratories merger reflected in this Exact Sciences (EXAS) Form 4?

The Form 4 shows Doyle’s shares being disposed of to the issuer at the merger’s effective time. Each Exact Sciences share outstanding was converted into the right to receive $105.00 in cash under the merger agreement with Abbott Laboratories, rather than sold on the market.

What consideration did Exact Sciences (EXAS) shareholders receive in the Abbott merger?

Each share of Exact Sciences common stock outstanding immediately before the effective time was converted into the right to receive $105.00 in cash, without interest. Restricted shares under company stock plans vested, were cancelled, and received the same $105.00 cash consideration, less any applicable tax withholding.

Did James Edward Doyle retain any Exact Sciences (EXAS) shares after the merger transaction?

No. After disposing of 52,564 shares and then 5,398 shares as issuer dispositions, Doyle’s reported direct ownership of Exact Sciences common stock was reduced to zero. His entire disclosed direct position was converted into the merger’s $105.00-per-share cash consideration structure.

Were Doyle’s Exact Sciences (EXAS) transactions open-market sales or merger-related disposals?

They were merger-related disposals coded as “D” for disposition to issuer, not open-market sales. The footnotes explain that, at the merger’s effective time, all outstanding and restricted shares converted into the right to receive $105.00 per share in cash under the merger agreement.

How were Exact Sciences (EXAS) restricted stock awards treated in the Abbott merger?

At the merger’s effective time, each share of Exact Sciences common stock subject to vesting or other restrictions became fully vested, was cancelled, and converted into the right to receive the $105.00 cash merger consideration, reduced by any required tax withholding amounts.